E-ISSN: 2147-1959
Unexpected Metastatic Localizations of Prostate Cancer Determined by <sup>68</sup>Ga PSMA PET/CT: Series of Four Cases
PDF
Cite
Share
Request
Interesting Image
VOLUME: 31 ISSUE: 3
P: 223-226
October 2022

Unexpected Metastatic Localizations of Prostate Cancer Determined by 68Ga PSMA PET/CT: Series of Four Cases

Mol Imaging Radionucl Ther 2022;31(3):223-226
DOI: 10.4274/mirt.galenos.2021.41033
Gözde Mütevelizade
Ceren Sezgin
Gül Gümüşer
Elvan Sayit
1. Manisa Celal Bayar University Faculty of Medicine, Department of Nuclear Medicine, Manisa, Turkey
No information available.
No information available
Received Date: 02.04.2021
Accepted Date: 16.06.2021
Publish Date: 19.10.2022
PDF
Cite
Share
Request

ABSTRACT

Prostate-specific membrane antigen (PSMA) is a transmembrane protein with overexpression in most prostate cancer cells. Gallium-68-(68Ga) PSMA positron emission tomography/computed tomography (PET/CT) imaging is a game-changer in the management of prostate cancer. 68Ga PSMA PET/CT scan is advanced and a promising radioligand has high sensitivity in determining lesions of prostate cancer with a high tumor to background ratio. The most common areas of metastasis are the bone and pelvic lymph nodes. The prognosis of prostate cancer is mainly determined by the status of metastases. The presence and the localization of metastases affects treatment planning. In our cases, we presented some examples of uncommon sites of metastases such as the brain, adrenal glands, penis and orbit. Improvements in imaging techniques, such as 68Ga PSMA PET/CT have led to the possibility to make more determi nation of rare metastase sites in prostate cancer patients.

References

1
Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, Hruby G, Fogarty G, Jagavkar R, Kneebone A, Hickey A, Fanti S, Tarlinton L, Emmett L. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med 2015;56:1185-1190.
2
Hatzoglou V, Patel GV, Morris MJ, Curtis K, Zhang Z, Shi W, Huse J, Rosenblum M, Holodny AI, Young RJ. Brain metastases from prostate cancer: an 11-year analysis in the MRI era with emphasis on imaging characteristics, incidence, and prognosis. J Neuroimaging 2014;24:161-166.
3
Dhamija E, Panda A, Das CJ, Gupta AK. Adrenal imaging (part 2): medullary and secondary adrenal lesions. Indian J Endocrinol Metab 2015;19:16-24.
4
Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000;31:578-583.
5
Tatkovic A, McBean R, Schoeman J, Wong D. Prostate penile metastasis: incidence and imaging pattern on 68Ga-PSMA PET/CT. J Med Imaging Radiat Oncol 2020;64:499-504.
6
Saadi A, Kerkeni W, Bouzouita A, Ayed H, Gaja A, Cherif M, Slama RB, Mnif N, Derouiche A, Chebil M. Bilateral orbital metastasis of prostatic adenocarcinoma. Urology 2016;94:e3-4.